Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print

Latest Articles in drugmaker

Gilead To Deliver More Remdesivir To Germany, Europe From The Fall

Remdesivir is currently the only drug granted a conditional marketing authorisation by the EU for its use in COVID-19 patients.

Read More

Mylan To Launch Generic Remdesivir Version In India At $64 Per 100 Mg Vial

Cipla will price its version, Cipremi, at less than 5,000 rupees, while Hetero has priced its version, Covifor, at 5,400 rupees

Read More

Emergent To Make Drug Substance For J&J's COVID-19 Vaccine Candidate

Johnson & Johnson had struck a deal with Emergent in April to use its manufacturing facilities and make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.

Read More

India Approves Human Trials For Second COVID-19 Vaccine Candidate

India's approval for Zydus comes days after privately held Bharat Biotech got a similar green light for human studies for its vaccine candidate.

Read More

Japan's Takeda Expects $200 Million Operating Loss Related To Novartis' Xiidra Withdrawal

Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.

Read More

India's Hetero Prices Experimental COVID-19 Drug Remdesivir At $71 Per 100 Mg Vial

India has approved the generic versions made by Cipla and Hetero for restricted emergency use in severe COVID-19 cases.

Read More

Sanofi Eyes Approval Of COVID-19 Vaccine By First Half Of 2021

There are currently no vaccines to prevent the coronavirus that has infected more than 9 million people and killed over 469,000 globally, and only a couple of medicines that have demonstrated benefit in hospitalized COVID-19 patients in clinical trials.

Read More

Sanofi Eyes Approval Of COVID-19 Vaccine By First Half Of 2021

Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021.

Read More

Alembic Pharma Gets EIR From USFDA For Its Panelav Facility

Shares of Alembic Pharmaceuticals were trading at Rs 940.05 per scrip on the BSE, up 3.50 per cent from its previous close.

Read More

Eli Lilly Starts Trial Of Rheumatoid Arthritis Drug In COVID-19 Patients

The trial is one of several efforts by the U.S. drugmaker to help combat the coronavirus pandemic, which has killed more than 400,000 people globally

Read More

France Expects AstraZeneca COVID-19 Vaccine To Be Shared Pro Rata

The British drugmaker signed a contract with European governments at the weekend to supply the region with up to 400 million doses of its potential vaccine.

Read More

AstraZeneca Wins Fresh US Backing In Race For COVID-19 Treatment

Companies and governments are scrambling to bring a solution for the illness caused by the new coronavirus to market as soon as possible

Read More

What Are Antibody Therapies And Who Is Developing Them For COVID-19?

COVID-19 treatment, researchers are studying the use of convalescent plasma and other treatments made with blood from recently recovered patients.

Read More

Pfizer Declines About 8% After Setback To Breast Cancer Treatment

Ibrance, approved by the U.S. Food and Drug Administration in 2015 for metastatic breast cancer, brought in sales of $4.96 billion in 2019.

Read More

Rising Swiss Rivalry As Roche And Novartis Target Same Diseases

Roche Chief Executive Severin Schwan is looking beyond cancer drugs to fresh treatment areas, while Novartis CEO Vas Narashiman bulks up in the same territory.

Read More